vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and KALA BIO, Inc. (KALA). Click either name above to swap in a different company.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ophthalmology therapies. It has a pipeline of product candidates addressing both common and rare eye diseases, targeting unmet medical needs and serving patients and healthcare providers mainly across the United States.
ASBP vs KALA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2022
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $0 |
| Net Profit | $-1.9M | $-12.8M |
| Gross Margin | 45.5% | — |
| Operating Margin | -59015.8% | — |
| Net Margin | -95337.1% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | 73.0% |
| EPS (diluted) | $-0.04 | $-7.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.9K | — | ||
| Q4 22 | — | $0 | ||
| Q3 22 | — | $420.0K | ||
| Q2 22 | — | $2.1M | ||
| Q1 22 | — | $1.4M |
| Q3 25 | $-1.9M | — | ||
| Q4 22 | — | $-12.8M | ||
| Q3 22 | — | $29.1M | ||
| Q2 22 | — | $-28.1M | ||
| Q1 22 | — | $-32.9M |
| Q3 25 | 45.5% | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | -59015.8% | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | -3468.8% | ||
| Q2 22 | — | -1236.8% | ||
| Q1 22 | — | -2253.2% |
| Q3 25 | -95337.1% | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | 6922.1% | ||
| Q2 22 | — | -1338.6% | ||
| Q1 22 | — | -2400.9% |
| Q3 25 | $-0.04 | — | ||
| Q4 22 | — | $-7.63 | ||
| Q3 22 | — | $19.25 | ||
| Q2 22 | — | $-18.92 | ||
| Q1 22 | — | $-22.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $70.5M |
| Total DebtLower is stronger | — | $43.3M |
| Stockholders' EquityBook value | $-11.5M | $19.0M |
| Total Assets | $2.4M | $86.8M |
| Debt / EquityLower = less leverage | — | 2.28× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q4 22 | — | $70.5M | ||
| Q3 22 | — | $52.4M | ||
| Q2 22 | — | $44.6M | ||
| Q1 22 | — | $70.2M |
| Q3 25 | — | — | ||
| Q4 22 | — | $43.3M | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | $-11.5M | — | ||
| Q4 22 | — | $19.0M | ||
| Q3 22 | — | $-968.0K | ||
| Q2 22 | — | $-31.6M | ||
| Q1 22 | — | $-5.3M |
| Q3 25 | $2.4M | — | ||
| Q4 22 | — | $86.8M | ||
| Q3 22 | — | $85.7M | ||
| Q2 22 | — | $85.0M | ||
| Q1 22 | — | $111.6M |
| Q3 25 | — | — | ||
| Q4 22 | — | 2.28× | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-13.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-1.1M | — | ||
| Q4 22 | — | $-13.7M | ||
| Q3 22 | — | $-15.7M | ||
| Q2 22 | — | $-25.4M | ||
| Q1 22 | — | $-24.1M |
| Q3 25 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | -0.54× | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
